Literature DB >> 23388656

Synthesis of selective inhibitors of sphingosine kinase 1.

Dong Jae Baek1, Neil MacRitchie, Nigel J Pyne, Susan Pyne, Robert Bittman.   

Abstract

Sphingosine kinase isoform 1 (SK1) inhibitors may serve as therapeutic agents for proliferative diseases, including hypertension. We synthesized a series of sphingosine-based SK1-selective inhibitors, the most potent of which is RB-005 (IC(50) = 3.6 μM), which also induced proteasomal degradation of SK1 in human pulmonary arterial smooth muscle cells.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23388656      PMCID： PMC3608193          DOI： 10.1039/c3cc00181d

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  19 in total

1.  The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells.

Authors:  Carolyn Loveridge; Francesca Tonelli; Tamara Leclercq; Keng Gat Lim; Jaclyn S Long; Evgeny Berdyshev; Rothwelle J Tate; Viswanathan Natarajan; Stuart M Pitson; Nigel J Pyne; Susan Pyne
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

2.  Antitumor activity of sphingosine kinase inhibitors.

Authors:  Kevin J French; John J Upson; Staci N Keller; Yan Zhuang; Jong K Yun; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2006-04-21       Impact factor: 4.030

3.  (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells.

Authors:  Keng Gat Lim; Chaode Sun; Robert Bittman; Nigel J Pyne; Susan Pyne
Journal:  Cell Signal       Date:  2011-05-18       Impact factor: 4.315

4.  Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle: a possible mechanism for augmented cell proliferation.

Authors:  D G Johns; R C Webb; J R Charpie
Journal:  J Hypertens       Date:  2001-01       Impact factor: 4.844

5.  Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.

Authors:  Mark E Schnute; Matthew D McReynolds; Tom Kasten; Matthew Yates; Gina Jerome; John W Rains; Troii Hall; Jill Chrencik; Michelle Kraus; Ciaran N Cronin; Matthew Saabye; Maureen K Highkin; Richard Broadus; Shinji Ogawa; Kristin Cukyne; Laura E Zawadzke; Vincent Peterkin; Kaliapan Iyanar; Jeffrey A Scholten; Jay Wendling; Hideji Fujiwara; Olga Nemirovskiy; Arthur J Wittwer; Marek M Nagiec
Journal:  Biochem J       Date:  2012-05-15       Impact factor: 3.857

Review 6.  Sphingosine 1-phosphate and cancer.

Authors:  Nigel J Pyne; Susan Pyne
Journal:  Nat Rev Cancer       Date:  2010-06-17       Impact factor: 60.716

7.  A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.

Authors:  Steven W Paugh; Barbara S Paugh; Mohamed Rahmani; Dmitri Kapitonov; Jorge A Almenara; Tomasz Kordula; Sheldon Milstien; Jeffrey K Adams; Robert E Zipkin; Steven Grant; Sarah Spiegel
Journal:  Blood       Date:  2008-05-29       Impact factor: 22.113

8.  Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.

Authors:  Nitai C Hait; Jeremy Allegood; Michael Maceyka; Graham M Strub; Kuzhuvelil B Harikumar; Sandeep K Singh; Cheng Luo; Ronen Marmorstein; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel
Journal:  Science       Date:  2009-09-04       Impact factor: 47.728

9.  Discovery and evaluation of inhibitors of human sphingosine kinase.

Authors:  Kevin J French; Randy S Schrecengost; Brian D Lee; Yan Zhuang; Staci N Smith; Justin L Eberly; Jong K Yun; Charles D Smith
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2.

Authors:  Sergio E Alvarez; Kuzhuvelil B Harikumar; Nitai C Hait; Jeremy Allegood; Graham M Strub; Eugene Y Kim; Michael Maceyka; Hualiang Jiang; Cheng Luo; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel
Journal:  Nature       Date:  2010-06-24       Impact factor: 49.962
View more
  20 in total

1.  Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells.

Authors:  Hoe-Sup Byun; Susan Pyne; Neil Macritchie; Nigel J Pyne; Robert Bittman
Journal:  Medchemcomm       Date:  2013       Impact factor: 3.597

2.  Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.

Authors:  Xijuan Liu; Jeremy M Simon; Haibiao Xie; Lianxin Hu; Jun Wang; Giada Zurlo; Cheng Fan; Travis S Ptacek; Laura Herring; Xianming Tan; Mingjie Li; Albert S Baldwin; William Y Kim; Tao Wu; Marc W Kirschner; Kan Gong; Qing Zhang
Journal:  Mol Cell       Date:  2020-02-04       Impact factor: 17.970

3.  An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors.

Authors:  Marcela Vettorazzi; Emilio Angelina; Santiago Lima; Tomas Gonec; Jan Otevrel; Pavlina Marvanova; Tereza Padrtova; Petr Mokry; Pavel Bobal; Lina M Acosta; Alirio Palma; Justo Cobo; Janette Bobalova; Jozef Csollei; Ivan Malik; Sergio Alvarez; Sarah Spiegel; Josef Jampilek; Ricardo D Enriz
Journal:  Eur J Med Chem       Date:  2017-08-10       Impact factor: 6.514

Review 4.  Sphingosine-1-phosphate metabolism: A structural perspective.

Authors:  Michael J Pulkoski-Gross; Jane C Donaldson; Lina M Obeid
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-04-29       Impact factor: 8.250

5.  Synthesis of (S)-FTY720 vinylphosphonate analogues and evaluation of their potential as sphingosine kinase 1 inhibitors and activators.

Authors:  Zheng Liu; Neil MacRitchie; Susan Pyne; Nigel J Pyne; Robert Bittman
Journal:  Bioorg Med Chem       Date:  2013-03-07       Impact factor: 3.641

Review 6.  Sphingosine kinase inhibitors: a review of patent literature (2006-2015).

Authors:  Kevin R Lynch; S Brandon Thorpe; Webster L Santos
Journal:  Expert Opin Ther Pat       Date:  2016-08-30       Impact factor: 6.674

7.  Effect of sphingosine kinase modulators on interleukin-1β release, sphingosine 1-phosphate receptor 1 expression and experimental autoimmune encephalomyelitis.

Authors:  Mark Barbour; Melissa McNaughton; Stephanie D Boomkamp; Neil MacRitchie; Hui-Rong Jiang; Nigel J Pyne; Susan Pyne
Journal:  Br J Pharmacol       Date:  2016-12-20       Impact factor: 8.739

8.  Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II.

Authors:  Francesca Cingolani; Mireia Casasampere; Pol Sanllehí; Josefina Casas; Jordi Bujons; Gemma Fabrias
Journal:  J Lipid Res       Date:  2014-05-29       Impact factor: 5.922

Review 9.  Molecular mechanisms of regulation of sphingosine kinase 1.

Authors:  Michael J Pulkoski-Gross; Lina M Obeid
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-30       Impact factor: 4.698

10.  Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeutics.

Authors:  Joanna M Woodcock; Carl Coolen; Katy L Goodwin; Dong Jae Baek; Robert Bittman; Michael S Samuel; Stuart M Pitson; Angel F Lopez
Journal:  Oncotarget       Date:  2015-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.